Explore opportunities

Search by company name (Bolden, Pax, OncoLux, Nabsys), asset id, or title. Each card links to a full dossier with cited evidence.

Loading filters…

Tier Aip_nanopieces_rna
Nanopieces non-viral RNA / nanocarrier delivery

Hospital-owned non-viral RNA nanocarriers—STTR-backed with expanded field-of-use option.

RIH assignee + R41TR002298—license to NanoDe or second newco beyond current scope.

Entity: NanoDe TherapeuticsPatents: 4Stage: preclinical sbir
US11701094B2US11608340B2US12357635B2US20230183253A1R41TR002298P20GM104416
Open dossier
Tier APatent gapgap_uri_phlip_lnp
PHLIP peptide–LNP nucleic acid & STING delivery (URI)

URI PHLIP delivers cargo into acidic tissues—LNP and STING programs without classic endocytosis.

URI tech transfer → RI spinout or license; Engelman/Reshetnyak PHLIP science (PMID 24659971).

Patents: 3Stage: preclinical grant
WO2025171027A1WO2025081077A1WO2024040027A1R01GM073857SourcePMID 24659971
Open dossier
Tier APatent gapgap_rih_bbb_nucleic_delivery
BBB-crossing nucleic acid delivery (RIH)

RIH platform for nucleic acid delivery across the blood–brain barrier.

Qian Chen (NanoDe peer) leads BBB nucleic delivery PCT; partner or license path.

Patents: 1Stage: preclinical grant
WO2025171161A1P30GM122732PMID 37513879
Open dossier
Research synthesis from public sources (NIH RePORTER, ClinicalTrials.gov, PubMed, USPTO, company press). Not investment advice, legal opinion, or clinical guidance. Verify cap tables, license chains, and trial status in data rooms before term sheets.